NeoGenomics, Inc. (NEO) key performance indicators and operating metrics (14 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Average revenue per clinical test | 515.00 | FY2026-Q2 |
| Clinical revenue growth excluding Pathline | 14.00 percent | FY2026-Q1 |
| Next-generation sequencing revenue growth | 26.00 percent | FY2026-Q2 |
| Adjusted gross margin | 48.00 percent | FY2026-Q2 |
| Adjusted earnings before interest, taxes, depreciation and amortization | 14M | FY2026-Q2 |
| Adjusted gross profit | 85.82M | FY2026-Q1 |
| Adjusted net income | 7M | FY2026-Q2 |
| Clinical Services average revenue per test | 488.00 USD_per_share | FY2025-Q4 |
| Adjusted earnings before interest, taxes, depreciation and amortization margin | 6.50 percent | FY2025-Q3 |
| Client Direct Billing revenue | 137.96M | FY2026-Q2 |
| Commercial Insurance revenue | 36.27M | FY2026-Q2 |
| Medicare And Other Governmental revenue | 27.43M | FY2026-Q2 |
| Reportable operating income | -9.77M | FY2026-Q2 |
| Self Pay Services revenue | -17K | FY2026-Q1 |
Back to NEO overview · NEO earnings · NEO holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.